Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2004 Jul;80(945):382–387. doi: 10.1136/pgmj.2003.014563

Scabies: more than just an irritation

J McCarthy 1, D Kemp 1, S Walton 1, B Currie 1
PMCID: PMC1743057  PMID: 15254301

Abstract

Human scabies, caused by skin infestation with the arthropod mite, Sarcoptes scabiei, typically results in a papular, intensely pruritic eruption involving the interdigital spaces, and flexure creases. Recent research has led to a reassessment of the morbidity attributable to this parasite in endemic communities, particularly resulting from secondary skin sepsis and postinfective complications including glomerulonephritis. This has led to studies of the benefits of community based control programmes, and to concerns regarding the emergence of drug resistance when such strategies are employed. The renewed research interest into the biology of this infection has resulted in the application of molecular tools. This has established that canine and human scabies populations are genetically distinct, a finding with major implications for the formulation of public health control policies. Further research is needed to increase understanding of drug resistance, and to identify new drug targets and potential vaccine candidates.

Full Text

The Full Text of this article is available as a PDF (211.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALBAHARY C., DUBRISAY J., GUERIN Pancytopénie rebelle au lindane (isomère de l'hexachlorocyclohexane). Arch Mal Prof. 1957 Nov-Dec;18(6):687–691. [PubMed] [Google Scholar]
  2. Arlian L. G. Biology, host relations, and epidemiology of Sarcoptes scabiei. Annu Rev Entomol. 1989;34:139–161. doi: 10.1146/annurev.en.34.010189.001035. [DOI] [PubMed] [Google Scholar]
  3. Arlian L. G., Morgan M. S., Vyszenski-Moher D. L., Stemmer B. L. Sarcoptes scabiei: the circulating antibody response and induced immunity to scabies. Exp Parasitol. 1994 Feb;78(1):37–50. doi: 10.1006/expr.1994.1004. [DOI] [PubMed] [Google Scholar]
  4. Arlian L. G., Rapp C. M., Morgan M. S. Resistance and immune response in scabies-infested hosts immunized with Dermatophagoides mites. Am J Trop Med Hyg. 1995 Jun;52(6):539–545. doi: 10.4269/ajtmh.1995.52.539. [DOI] [PubMed] [Google Scholar]
  5. Arlian L. G., Vyszenski-Moher D. L., Pole M. J. Survival of adults and development stages of Sarcoptes scabiei var. canis when off the host. Exp Appl Acarol. 1989 Apr;6(3):181–187. doi: 10.1007/BF01193978. [DOI] [PubMed] [Google Scholar]
  6. Barkwell R., Shields S. Deaths associated with ivermectin treatment of scabies. Lancet. 1997 Apr 19;349(9059):1144–1145. doi: 10.1016/S0140-6736(05)63020-6. [DOI] [PubMed] [Google Scholar]
  7. Boix V., Sánchez-Payá J., Portilla J., Merino E. Nosocomial outbreak of scabies clinically resistant to lindane. Infect Control Hosp Epidemiol. 1997 Oct;18(10):677–677. doi: 10.1086/647507. [DOI] [PubMed] [Google Scholar]
  8. Boué O., Redondo M., Montero C., Rodríguez M., de la Fuente J. Reproductive and safety assessment of vaccination with Gavac against the cattle tick (Boophilus microplus). Theriogenology. 1999 Jun;51(8):1547–1554. doi: 10.1016/s0093-691x(99)00097-7. [DOI] [PubMed] [Google Scholar]
  9. Carapetis J. R., Connors C., Yarmirr D., Krause V., Currie B. J. Success of a scabies control program in an Australian aboriginal community. Pediatr Infect Dis J. 1997 May;16(5):494–499. doi: 10.1097/00006454-199705000-00008. [DOI] [PubMed] [Google Scholar]
  10. Cargill C. F., Pointon A. M., Davies P. R., Garcia R. Using slaughter inspections to evaluate sarcoptic mange infestation of finishing swine. Vet Parasitol. 1997 Jun;70(1-3):191–200. doi: 10.1016/s0304-4017(96)01137-5. [DOI] [PubMed] [Google Scholar]
  11. Coyne P. E., Addiss D. G. Deaths associated with ivermectin for scabies. Lancet. 1997 Jul 19;350(9072):215–216. doi: 10.1016/S0140-6736(05)62378-1. [DOI] [PubMed] [Google Scholar]
  12. Currie B. J., Carapetis J. R. Skin infections and infestations in Aboriginal communities in northern Australia. Australas J Dermatol. 2000 Aug;41(3):139–145. doi: 10.1046/j.1440-0960.2000.00417.x. [DOI] [PubMed] [Google Scholar]
  13. Currie B. J., Connors C. M., Krause V. L. Scabies programs in aboriginal communities. Med J Aust. 1994 Nov 21;161(10):636–637. doi: 10.5694/j.1326-5377.1994.tb127655.x. [DOI] [PubMed] [Google Scholar]
  14. Currie B. J., Maguire G. P., Wood Y. K. Ivermectin and crusted (Norwegian) scabies. Med J Aust. 1995 Nov 20;163(10):559–560. doi: 10.5694/j.1326-5377.1995.tb124745.x. [DOI] [PubMed] [Google Scholar]
  15. Davis D. P., Moon R. D. Dynamics of swine mange: a critical review of the literature. J Med Entomol. 1990 Sep;27(5):727–737. doi: 10.1093/jmedent/27.5.727. [DOI] [PubMed] [Google Scholar]
  16. Degelau J. Scabies in long-term care facilities. Infect Control Hosp Epidemiol. 1992 Jul;13(7):421–425. doi: 10.1086/646561. [DOI] [PubMed] [Google Scholar]
  17. Elgart M. L. A risk-benefit assessment of agents used in the treatment of scabies. Drug Saf. 1996 Jun;14(6):386–393. doi: 10.2165/00002018-199614060-00004. [DOI] [PubMed] [Google Scholar]
  18. Elmogy M., Fayed H., Marzok H., Rashad A. Oral ivermectin in the treatment of scabies. Int J Dermatol. 1999 Dec;38(12):926–928. doi: 10.1046/j.1365-4362.1999.00865.x. [DOI] [PubMed] [Google Scholar]
  19. Friedman S. J. Lindane neurotoxic reaction in nonbullous congenital ichthyosiform erythroderma. Arch Dermatol. 1987 Aug;123(8):1056–1058. [PubMed] [Google Scholar]
  20. Gogna N. K., Lee K. C., Howe D. W. Norwegian scabies in Australian Aborigines. Med J Aust. 1985 Jan 21;142(2):140–142. [PubMed] [Google Scholar]
  21. Hersch C. Acute glomerulonephritis due to skin disease, with special reference to scabies. S Afr Med J. 1967 Jan 14;41(2):29–34. [PubMed] [Google Scholar]
  22. Hogan D. J., Schachner L., Tanglertsampan C. Diagnosis and treatment of childhood scabies and pediculosis. Pediatr Clin North Am. 1991 Aug;38(4):941–957. doi: 10.1016/s0031-3955(16)38161-5. [DOI] [PubMed] [Google Scholar]
  23. Huffam S. E., Currie B. J. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis. 1998 Jan-Mar;2(3):152–154. doi: 10.1016/s1201-9712(98)90118-7. [DOI] [PubMed] [Google Scholar]
  24. Hulbert T. V., Larsen R. A. Hyperkeratotic (Norwegian) scabies with gram-negative bacteremia as the initial presentation of AIDS. Clin Infect Dis. 1992 May;14(5):1164–1165. doi: 10.1093/clinids/14.5.1164. [DOI] [PubMed] [Google Scholar]
  25. Meinking T. L., Taplin D., Hermida J. L., Pardo R., Kerdel F. A. The treatment of scabies with ivermectin. N Engl J Med. 1995 Jul 6;333(1):26–30. doi: 10.1056/NEJM199507063330105. [DOI] [PubMed] [Google Scholar]
  26. Mellanby K. Scabies in 1976. R Soc Health J. 1977 Feb;97(1):32-6, 40. doi: 10.1177/146642407709700112. [DOI] [PubMed] [Google Scholar]
  27. Nair B. K., Joseph A., Kandamuthan M. Epidemic scabies. Indian J Med Res. 1977 Apr;65(4):513–518. [PubMed] [Google Scholar]
  28. Orkin M. Resurgence of scabies. JAMA. 1971 Aug 2;217(5):593–597. [PubMed] [Google Scholar]
  29. Parent-Massin D., Thouvenot D., Rio B., Riche C. Lindane haematotoxicity confirmed by in vitro tests on human and rat progenitors. Hum Exp Toxicol. 1994 Feb;13(2):103–106. doi: 10.1177/096032719401300207. [DOI] [PubMed] [Google Scholar]
  30. Pence D. B., Ueckermann E. Sarcoptic manage in wildlife. Rev Sci Tech. 2002 Aug;21(2):385–398. [PubMed] [Google Scholar]
  31. Pettit D., Smith W. D., Richardson J., Munn E. A. Localisation and characterisation of ovine immunglobulin within the sheep scab mite, Psoroptes ovis. Vet Parasitol. 2000 Apr 28;89(3):231–239. doi: 10.1016/s0304-4017(00)00203-x. [DOI] [PubMed] [Google Scholar]
  32. Rauch A. E., Kowalsky S. F., Lesar T. S., Sauerbier G. A., Burkart P. T., Scharfman W. B. Lindane (Kwell)-induced aplastic anemia. Arch Intern Med. 1990 Nov;150(11):2393–2395. [PubMed] [Google Scholar]
  33. Reintjes R., Hoek C. Deaths associated with ivermectin for scabies. Lancet. 1997 Jul 19;350(9072):215–216. doi: 10.1016/S0140-6736(05)62377-X. [DOI] [PubMed] [Google Scholar]
  34. Roos T. C., Alam M., Roos S., Merk H. F., Bickers D. R. Pharmacotherapy of ectoparasitic infections. Drugs. 2001;61(8):1067–1088. doi: 10.2165/00003495-200161080-00004. [DOI] [PubMed] [Google Scholar]
  35. Stromberg P. C., Fisher W. F. Dermatopathology and immunity in experimental Psoroptes ovis (Acari:Psoroptidae) infestation of naive and previously exposed Hereford cattle. Am J Vet Res. 1986 Jul;47(7):1551–1560. [PubMed] [Google Scholar]
  36. Sullivan J. R., Watt G., Barker B. Successful use of ivermectin in the treatment of endemic scabies in a nursing home. Australas J Dermatol. 1997 Aug;38(3):137–140. doi: 10.1111/j.1440-0960.1997.tb01130.x. [DOI] [PubMed] [Google Scholar]
  37. Svartman M., Finklea J. F., Earle D. P., Potter E. V., Poon-King T. Epidemic scabies and acute glomerulonephritis in Trinidad. Lancet. 1972 Jan 29;1(7744):249–251. doi: 10.1016/s0140-6736(72)90634-4. [DOI] [PubMed] [Google Scholar]
  38. Taplin D., Meinking T. L., Chen J. A., Sanchez R. Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Pediatr Dermatol. 1990 Mar;7(1):67–73. doi: 10.1111/j.1525-1470.1990.tb01078.x. [DOI] [PubMed] [Google Scholar]
  39. Taplin D., Porcelain S. L., Meinking T. L., Athey R. L., Chen J. A., Castillero P. M., Sanchez R. Community control of scabies: a model based on use of permethrin cream. Lancet. 1991 Apr 27;337(8748):1016–1018. doi: 10.1016/0140-6736(91)92669-s. [DOI] [PubMed] [Google Scholar]
  40. Taplin D., Rivera A., Walker J. G., Roth W. I., Reno D., Meinking T. A comparative trial of three treatment schedules for the eradication of scabies. J Am Acad Dermatol. 1983 Oct;9(4):550–554. doi: 10.1016/s0190-9622(83)70168-4. [DOI] [PubMed] [Google Scholar]
  41. Van Neste D., Lachapelle J. M. Host-parasite relationships in hyperkeratotic (Norwegian) scabies: pathological and immunological findings. Br J Dermatol. 1981 Dec;105(6):667–678. doi: 10.1111/j.1365-2133.1981.tb00977.x. [DOI] [PubMed] [Google Scholar]
  42. Walker G. J., Johnstone P. W. Interventions for treating scabies. Cochrane Database Syst Rev. 2000;(3):CD000320–CD000320. doi: 10.1002/14651858.CD000320. [DOI] [PubMed] [Google Scholar]
  43. Walton S. F., McBroom J., Mathews J. D., Kemp D. J., Currie B. J. Crusted scabies: A molecular analysis of Sarcoptes scabiei variety hominis populations from patients with repeated infestations. Clin Infect Dis. 1999 Nov;29(5):1226–1230. doi: 10.1086/313466. [DOI] [PubMed] [Google Scholar]
  44. Walton S. F., Myerscough M. R., Currie B. J. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg. 2000 Jan-Feb;94(1):92–96. doi: 10.1016/s0035-9203(00)90454-1. [DOI] [PubMed] [Google Scholar]
  45. Willadsen P. Novel vaccines for ectoparasites. Vet Parasitol. 1997 Jul 31;71(2-3):209–222. doi: 10.1016/s0304-4017(97)00028-9. [DOI] [PubMed] [Google Scholar]
  46. Wong L. C., Amega B., Connors C., Barker R., Dulla M. E., Ninnal A., Kolumboort L., Cumaiyi M. M., Currie B. J. Outcome of an interventional program for scabies in an Indigenous community. Med J Aust. 2001 Oct 1;175(7):367–370. doi: 10.5694/j.1326-5377.2001.tb143620.x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES